These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 22157459)
1. Anaemia tolerance: bridging with intravenous ferric carboxymaltose in a patient with acute post-haemorrhagic anaemia. Hönemann CW; Doll D; Kampmeier T; Ertmer C; Hagemann O; Hahnenkamp K Br J Anaesth; 2012 Jan; 108(1):167-8. PubMed ID: 22157459 [No Abstract] [Full Text] [Related]
2. "Camel humps"-shaped red blood cell histogram in a woman with extreme anemia treated with intravenous iron. Beverina I; Scalvini R; Brando B Transfusion; 2021 Feb; 61(2):348-349. PubMed ID: 33111350 [No Abstract] [Full Text] [Related]
3. [Intravenous ferric carboxymaltose for the treatment of anemia in chronic renal disease]. Merino JL; Bueno B; Campos MA; Amézquita Y Rev Clin Esp (Barc); 2014; 214(5):282-3. PubMed ID: 24582410 [No Abstract] [Full Text] [Related]
4. A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. Bisbe E; García-Erce JA; Díez-Lobo AI; Muñoz M; Br J Anaesth; 2011 Sep; 107(3):477-8. PubMed ID: 21841061 [No Abstract] [Full Text] [Related]
5. Iron supplementation in a case of severe iron deficiency anaemia. Füllenbach C; Triphaus C; Glaser P; Ziebart A; Zacharowski K; Meybohm P; Choorapoikayil S Br J Anaesth; 2018 Aug; 121(2):502-504. PubMed ID: 30032895 [No Abstract] [Full Text] [Related]
6. Intravenous ferric carboxymaltose for iron deficiency anaemia in pregnancy. Nwagha UI; Nwagha TU Lancet Glob Health; 2024 Oct; 12(10):e1567-e1568. PubMed ID: 39304228 [No Abstract] [Full Text] [Related]
7. Ferric carboxymaltose: a review of its use in iron deficiency. Keating GM Drugs; 2015 Jan; 75(1):101-27. PubMed ID: 25428711 [TBL] [Abstract][Full Text] [Related]
8. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status. Toblli JE; Di Gennaro F PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811 [TBL] [Abstract][Full Text] [Related]
9. Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. Calleja JL; Delgado S; del Val A; Hervás A; Larraona JL; Terán Á; Cucala M; Mearin F; Int J Colorectal Dis; 2016 Mar; 31(3):543-51. PubMed ID: 26694926 [TBL] [Abstract][Full Text] [Related]
10. Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life. Befrits R; Wikman O; Blomquist L; Hjortswang H; Hammarlund P; Bajor A; Klintman D; Blom H Scand J Gastroenterol; 2013 Sep; 48(9):1027-32. PubMed ID: 23889159 [TBL] [Abstract][Full Text] [Related]
11. FAIRY: a randomized controlled patient-blind phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose (Ferinject®) to placebo in patients with acute isovolemic anemia after gastrectomy - study protocol for a randomized controlled trial. Reim D; Kim YW; Nam BH; Kim MJ; Yook JH; Park YK; Roh SH; Yu WS; Bae JM Trials; 2014 Apr; 15():111. PubMed ID: 24708660 [TBL] [Abstract][Full Text] [Related]
12. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease. Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S Digestion; 2012; 85(1):47-54. PubMed ID: 22179489 [TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding. Mahey R; Kriplani A; Mogili KD; Bhatla N; Kachhawa G; Saxena R Int J Gynaecol Obstet; 2016 Apr; 133(1):43-8. PubMed ID: 26868063 [TBL] [Abstract][Full Text] [Related]
14. Preoperative Intravenous Iron in Anemic Patients Undergoing Major Abdominal Surgery May Not PREVENTT Blood Transfusions But Still Contribute to the Objectives of Patient Blood Management. Hardy JF; Farmer SL; Auerbach M; Frank SM; Javidroozi M; Leahy MF; Meier J; Ozawa S; Shander A Anesth Analg; 2021 Apr; 132(4):1174-1177. PubMed ID: 33723195 [No Abstract] [Full Text] [Related]
15. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Van Wyck DB; Martens MG; Seid MH; Baker JB; Mangione A Obstet Gynecol; 2007 Aug; 110(2 Pt 1):267-78. PubMed ID: 17666600 [TBL] [Abstract][Full Text] [Related]
16. Preoperative Intravenous Iron and Erythropoietin to Treat Severe Anemia in Patient With Stage 4 Kidney Disease Before Oncologic Surgery: A Case Report. Luan-Erfe BM; Yilmaz M; Sweitzer B A A Pract; 2020 Jun; 14(8):e01234. PubMed ID: 32496428 [TBL] [Abstract][Full Text] [Related]
17. Ferric Carboxymaltose in the treatment of chemotherapy-induced anaemia: an effective, safe and cost- sparing alternative to blood transfusion. Marinho J; Leão I; Custódio S; Dias E; Moreira Pinto A; Costa T; Capela A; Dias M; Coelho H; Cunha Â; Macedo A; Amarelo A; Joaquim A Sci Rep; 2019 Dec; 9(1):20410. PubMed ID: 31892732 [TBL] [Abstract][Full Text] [Related]
18. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose. Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271 [TBL] [Abstract][Full Text] [Related]
19. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective. Luporsi E; Mahi L; Morre C; Wernli J; de Pouvourville G; Bugat R J Med Econ; 2012; 15(2):225-32. PubMed ID: 22077267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]